18h
Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses
Connect Biopharma (NASDAQ:CNTB) shared new clinical and preclinical updates on rademikibart, its IL-4 receptor alpha ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results